Roth Capital Analysts Lift Earnings Estimates for Longeveron

Longeveron Inc. (NASDAQ:LGVN) – Equities researchers at Roth Capital raised their Q1 2025 earnings estimates for shares of Longeveron in a note issued to investors on Monday, March 3rd. Roth Capital analyst B. Pachaiyappan now anticipates that the company will post earnings of ($0.30) per share for the quarter, up from their prior estimate of ($0.36). Roth Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Longeveron’s current full-year earnings is ($3.69) per share. Roth Capital also issued estimates for Longeveron’s Q2 2025 earnings at ($0.33) EPS, Q3 2025 earnings at ($0.37) EPS and FY2025 earnings at ($1.40) EPS.

Other equities research analysts also recently issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Longeveron in a report on Monday. Roth Mkm began coverage on shares of Longeveron in a report on Friday, December 6th. They set a “buy” rating and a $10.00 price objective on the stock.

Longeveron Stock Up 5.3 %

NASDAQ LGVN opened at $1.40 on Thursday. The company has a market cap of $20.77 million, a PE ratio of -0.22 and a beta of 0.36. Longeveron has a 52 week low of $0.77 and a 52 week high of $6.40. The firm’s 50-day simple moving average is $1.64 and its two-hundred day simple moving average is $1.89.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. State Street Corp bought a new position in shares of Longeveron in the third quarter worth approximately $29,000. Northern Trust Corp purchased a new stake in shares of Longeveron during the fourth quarter valued at approximately $31,000. Jane Street Group LLC purchased a new stake in shares of Longeveron during the fourth quarter valued at approximately $35,000. Virtu Financial LLC purchased a new stake in shares of Longeveron during the fourth quarter valued at approximately $53,000. Finally, Geode Capital Management LLC boosted its stake in shares of Longeveron by 316.0% during the third quarter. Geode Capital Management LLC now owns 128,947 shares of the company’s stock valued at $250,000 after purchasing an additional 97,953 shares during the period. 10.01% of the stock is currently owned by institutional investors.

About Longeveron

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.